Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,597

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

Open access
Marty, Michel, Cognetti, Francesco, Maraninchi, Dominique, Snyder, Ray, Mauriac, Louis, Tubiana-Hulin, Michèle, Chan, Stephen, Grimes, David, Antón, Antonio, Lluch, Ana, Kennedy, John, O’Byrne, Kenneth, Conte, PierFranco, Green, Michael, Ward, Carol, Mayne, Karen, Extra, Jean-Marc · 2005 · Journal of Clinical Oncology

Abstract

Purpose: This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) –positive metastatic breast cancer (MBC). Patients and Methods: Patients were randomly assigned to six cycles of docetaxel 100 mg/m 2 every 3 weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly until disease progression. Results: A total of 186 patients received at least one dose of the study drug. Trastuzumab plus docetaxel was significantly superior to docetaxel alone in terms of overall response rate (61% v 34%; P = .0002), overall survival (median, 31.2 v 22.7 months; P = .0325), time to disease progression (median, 11.7 v 6.1 months; P = .0001), time to treatment failure (median, 9.8 v 5.3 months; P = .0001), and duration of response (median, 11.7 v 5.7 months; P = .009). There was little difference in the number and severity of adverse events between the arms. Grade 3 to 4 neutropenia was seen more commonly with the combination (32%) than with docetaxel alone (22%), and there was a slightly higher incidence of febrile neutropenia in the combination arm (23% v 17%). One patient in the combination arm experienced symptomatic heart failure (1%). Another patient experienced symptomatic heart failure 5 months after discontinuation of trastuzumab because of disease progression, while being treated with an investigational anthracycline for 4 months. Conclusion: Trastuzumab combined with docetaxel is superior to docetaxel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.04.173

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 9

  1. 10.1200/JCO.20.3.719 · DOI · Paper page
  2. Bauer-Kosińska B, Lemanska I, Glogowska I, et al: Efficacy and toxicity of docetaxel or cisplatin chemotherapy in combination with trastuzumab in the treatment of patients with chemotherapy pre-treated HER-2/neu overexpressed metastatic breast cancer. Eur J Cancer 1:S141,2003, (suppl 5; abstr 464) · doi:10.1016/s1359-6349(03)90496-4
  3. Montemurro F, Choa G, Faggiuolo R, et al: Safety and activity of docetaxel and trastuzumab in HER2 overexpressing breast cancer: A pilot phase II study. Am J Clin Oncol 26:95,2003-97, · doi:10.1097/01.coc.0000017087.19671.05
  4. Tabei T, Kimura M, Sano M, et al: Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing metastatic breast cancer patients: Japan East Cancer Center Breast Cancer Consortium (JECBC 01 trial). Eur J Cancer 2:131,2004, (suppl 3; abstr 258) · doi:10.1016/s1359-6349(04)90861-0
  5. 10.3816/CBC.2004.n.005 · doi:10.3816/cbc.2004.n.005
  6. 10.1023/A:1020587504186 · doi:10.1023/a:1020587504186
  7. Takao S, Kohno N, Miyashita M, et al: Weekly docetaxel and trastuzumab for her2-overexpressing metastatic breast cancer: Efficacy and correlation with biological markers in a phase II, multicenter study. Eur J Cancer 2:137,2004, (suppl 3; abstr 280) · doi:10.1016/s1359-6349(04)90883-x
  8. 10.1023/A:1020587504186 · doi:10.1023/a:1020587504186
  9. Baselga J, Climent MA, Lluch A, et al: Results of a phase II study of liposomal doxorubicin (Myocet) in combination with weekly paclitaxel and trastuzumab (Herceptin) in patientswith HER2-positive locally advanced or metastatic breast cancer (LA/MBC). Eur J Cancer 2:132,2004, (suppl 3; abstr 262) · doi:10.1016/s1359-6349(04)90865-8

Cited by

See all 1,597

Metadata

Authors
Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., Antón, A., Lluch, A., Kennedy, J., O’Byrne, K., Conte, P., Green, M., Ward, C., Mayne, K., & Extra, J.-M.
Venue
Journal of Clinical Oncology
Published
2005-07-01
Volume
23
Issue
19
Pages
4265-4274
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1531524380
Cited by
1,597
References
17
FWCI
45.65
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.